StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.05+0.01 (+0.25%)

Close on Nov 17, 2026Market cap $336.94MP/E –Yield –

Opus Genetics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Opus Genetics's operating cash flow for the twelve months ending Jun 30, 2026 was -$40.67M. For fiscal 2025 it was -$35.25M. The highest annual figure on record is $14.31M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$35.25M–
FY2024Dec 31, 2024-$25.58M–
FY2023Dec 31, 2023-$1.11M-107.8%
FY2022Dec 31, 2022$14.31M–
FY2021Dec 31, 2021-$19.37M–
FY2020Dec 31, 2020-$6.80M–
FY2019Dec 31, 2019-$3.59M–
FY2018Dec 31, 2018-$18.84M–
FY2017Dec 31, 2017-$15.42M–
FY2016Dec 31, 2016-$13.23M–
FY2015Dec 31, 2015-$17.35M–
FY2014Dec 31, 2014-$11.04M–
FY2013Dec 31, 2013-$7.98M–
FY2012Dec 31, 2012-$6.62M–
FY2011Dec 31, 2011-$15.53M–
FY2010Dec 31, 2010-$6.99M–
FY2009Dec 31, 2009-$5.15M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.95M–
Q1 FY2026Mar 31, 2026-$12.73M–
Q4 FY2025Dec 31, 2025-$9.83M–
Q3 FY2025Sep 30, 2025-$6.16M–
Q2 FY2025Jun 30, 2025-$10.27M–
Q1 FY2025Mar 31, 2025-$8.99M–
Q4 FY2024Dec 31, 2024-$7.44M-263.5%
Q3 FY2024Sep 30, 2024-$5.13M–
Q2 FY2024Jun 30, 2024-$7.29M-837.3%
Q1 FY2024Mar 31, 2024-$5.72M–
Q4 FY2023Dec 31, 2023$4.55M-84.2%
Q3 FY2023Sep 30, 2023-$3.00M–
Q2 FY2023Jun 30, 2023$989.00K–
Q1 FY2023Mar 31, 2023-$3.65M–
Q4 FY2022Dec 31, 2022$28.79M–
Q3 FY2022Sep 30, 2022-$4.50M–
Q2 FY2022Jun 30, 2022-$3.81M–
Q1 FY2022Mar 31, 2022-$6.17M–
Q4 FY2021Dec 31, 2021-$5.65M–
Q3 FY2021Sep 30, 2021-$3.58M–
Q2 FY2021Jun 30, 2021-$4.33M–
Q1 FY2021Mar 31, 2021-$5.81M–
Q4 FY2020Dec 31, 2020-$4.36M-187.7%
Q3 FY2020Sep 30, 2020-$1.06M–
Q2 FY2020Jun 30, 2020-$651.00K–
Q1 FY2020Mar 31, 2020-$732.00K–
Q4 FY2019Dec 31, 2019$4.97M–
Q3 FY2019Sep 30, 2019-$2.38M–
Q2 FY2019Jun 30, 2019-$1.81M–
Q1 FY2019Mar 31, 2019-$4.38M–
Q4 FY2018Dec 31, 2018-$4.62M–
Q3 FY2018Sep 30, 2018-$4.17M–
Q2 FY2018Jun 30, 2018-$4.45M–
Q1 FY2018Mar 31, 2018-$5.60M–
Q4 FY2017Dec 31, 2017-$3.70M–
Q3 FY2017Sep 30, 2017-$3.45M–
Q2 FY2017Jun 30, 2017-$4.10M–
Q1 FY2017Mar 31, 2017-$4.17M–
Q4 FY2016Dec 31, 2016-$1.49M–
Q3 FY2016Sep 30, 2016-$3.12M–

More Opus Genetics figures

See a number that looks wrong?